vs
Side-by-side financial comparison of Atara Biotherapeutics, Inc. (ATRA) and Glimpse Group, Inc. (VRAR). Click either name above to swap in a different company.
Atara Biotherapeutics, Inc. is the larger business by last-quarter revenue ($1.6M vs $1.3M, roughly 1.2× Glimpse Group, Inc.). On growth, Glimpse Group, Inc. posted the faster year-over-year revenue change (-59.0% vs -95.1%).
Atara Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing allogeneic T-cell immunotherapies for patients with unmet medical needs across oncology, autoimmune disease, and infectious disease indications. It operates primarily in North America, Europe, and Asia-Pacific, partnering with research institutions to advance its novel treatment pipeline.
The Glimpse Group, Inc. is a specialized immersive technology firm focused on developing virtual reality (VR) and augmented reality (AR) solutions. It serves enterprise, education, healthcare, and entertainment segments, offering custom immersive experiences and software tools for clients across North America and select global markets.
ATRA vs VRAR — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.6M | $1.3M |
| Net Profit | — | $-1.2M |
| Gross Margin | — | 60.7% |
| Operating Margin | — | -97.1% |
| Net Margin | — | -94.3% |
| Revenue YoY | -95.1% | -59.0% |
| Net Profit YoY | 73.2% | -4837.1% |
| EPS (diluted) | — | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.6M | $1.3M | ||
| Q3 25 | $3.5M | $1.4M | ||
| Q2 25 | $17.6M | — | ||
| Q1 25 | $98.1M | — | ||
| Q4 24 | $32.8M | — | ||
| Q3 24 | $40.2M | — | ||
| Q2 24 | $28.6M | — | ||
| Q1 24 | $27.4M | — |
| Q4 25 | — | $-1.2M | ||
| Q3 25 | $-4.3M | $-1.0M | ||
| Q2 25 | $2.4M | — | ||
| Q1 25 | $38.0M | — | ||
| Q4 24 | $-12.7M | — | ||
| Q3 24 | $-21.9M | — | ||
| Q2 24 | $-19.0M | — | ||
| Q1 24 | $-31.8M | — |
| Q4 25 | — | 60.7% | ||
| Q3 25 | — | 72.1% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | -97.1% | ||
| Q3 25 | -103.5% | -95.6% | ||
| Q2 25 | 18.2% | — | ||
| Q1 25 | 39.5% | — | ||
| Q4 24 | -37.3% | — | ||
| Q3 24 | -54.1% | — | ||
| Q2 24 | -63.7% | — | ||
| Q1 24 | -114.2% | — |
| Q4 25 | — | -94.3% | ||
| Q3 25 | -124.6% | -73.9% | ||
| Q2 25 | 13.6% | — | ||
| Q1 25 | 38.7% | — | ||
| Q4 24 | -38.8% | — | ||
| Q3 24 | -54.5% | — | ||
| Q2 24 | -66.5% | — | ||
| Q1 24 | -116.1% | — |
| Q4 25 | — | $-0.06 | ||
| Q3 25 | $-0.32 | $-0.05 | ||
| Q2 25 | $0.19 | — | ||
| Q1 25 | $3.50 | — | ||
| Q4 24 | $0.27 | — | ||
| Q3 24 | $-2.93 | — | ||
| Q2 24 | $-3.10 | — | ||
| Q1 24 | $-5.65 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $8.5M | $3.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-38.5M | $15.3M |
| Total Assets | $20.2M | $16.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $8.5M | $3.3M | ||
| Q3 25 | $13.7M | $5.6M | ||
| Q2 25 | $22.3M | — | ||
| Q1 25 | $13.8M | — | ||
| Q4 24 | $42.5M | — | ||
| Q3 24 | $67.2M | — | ||
| Q2 24 | $35.3M | — | ||
| Q1 24 | $46.2M | — |
| Q4 25 | $-38.5M | $15.3M | ||
| Q3 25 | $-36.6M | $16.2M | ||
| Q2 25 | $-35.0M | — | ||
| Q1 25 | $-55.1M | — | ||
| Q4 24 | $-97.3M | — | ||
| Q3 24 | $-90.5M | — | ||
| Q2 24 | $-110.9M | — | ||
| Q1 24 | $-98.3M | — |
| Q4 25 | $20.2M | $16.0M | ||
| Q3 25 | $30.2M | $18.3M | ||
| Q2 25 | $36.9M | — | ||
| Q1 25 | $62.0M | — | ||
| Q4 24 | $109.1M | — | ||
| Q3 24 | $142.7M | — | ||
| Q2 24 | $117.3M | — | ||
| Q1 24 | $165.3M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-50.9M | $-739.2K |
| Free Cash FlowOCF − Capex | — | $-747.3K |
| FCF MarginFCF / Revenue | — | -57.5% |
| Capex IntensityCapex / Revenue | 0.0% | 0.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-50.9M | $-739.2K | ||
| Q3 25 | $-9.8M | $-1.3M | ||
| Q2 25 | $-7.3M | — | ||
| Q1 25 | $-28.1M | — | ||
| Q4 24 | $-24.5M | — | ||
| Q3 24 | $-4.0M | — | ||
| Q2 24 | $-10.6M | — | ||
| Q1 24 | $-29.6M | — |
| Q4 25 | — | $-747.3K | ||
| Q3 25 | — | $-1.3M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $-24.6M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-10.7M | — | ||
| Q1 24 | $-29.7M | — |
| Q4 25 | — | -57.5% | ||
| Q3 25 | — | -92.8% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -75.0% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -37.3% | — | ||
| Q1 24 | -108.7% | — |
| Q4 25 | 0.0% | 0.6% | ||
| Q3 25 | 0.0% | 0.6% | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.3% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.1% | — | ||
| Q1 24 | 0.5% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -3.07× | — | ||
| Q1 25 | -0.74× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ATRA
Segment breakdown not available.
VRAR
| Software Services | $1.2M | 90% |
| Other | $124.4K | 10% |
